Medtronic reported third-quarter fiscal 2026 revenue of $9.02 billion, surpassing Wall Street consensus estimates of $8.91 billion and representing 8.7% year-over-year growth. The company's organic revenue expansion reached 6% for the quarter, demonstrating broad-based performance across its portfolio. Management reaffirmed its full-year fiscal 2026 guidance, projecting 5.5% organic revenue growth with adjusted earnings per share guidance of $5.62 to $5.66.
The medical technology company's strong quarterly results were predominantly driven by its Cardiovascular Portfolio, which posted 10.6% organic growth and continued its momentum in structural heart and coronary interventions. The Diabetes business segment also delivered robust performance with 8.3% organic growth, reflecting sustained demand for its insulin delivery and continuous glucose monitoring solutions. These two segments collectively demonstrated the strength of Medtronic's focus on high-growth therapeutic areas.
Despite beating both revenue and earnings expectations, Medtronic's stock declined 2.84% following the earnings announcement, a response that underscores broader market dynamics and potential investor expectations for acceleration beyond current guidance levels. The company's maintained outlook suggests management confidence in executing its strategic priorities throughout the remainder of fiscal 2026.